Hodgkin's Lymphoma Treatment

Hodgkin’s lymphoma is one of the most curable forms of cancer. Most people respond well to treatment and the overall 5-year survival rate is 85%, with most of those individuals having been cured of the disease.

Hodgkin’s lymphoma is treated with chemotherapy alone or a combination of chemotherapy and radiotherapy. The specific treatment plan for any individual depends on factors such as the patient’s age, their general health status and suitability for chemotherapy, and the stage and subtype of the cancer.

The treatment approach to Hodgkin’s lymphoma is outlined below:

Chemotherapy – Although chemotherapy agents kill fast growing cancer cells, they also kill healthy fast growing cells in parts of the body such as the blood, skin and stomach. This can lead to symptoms such as anemia, susceptibility to infection and diarrhea and sickness and patients may feel weak, sick and fatigued as well as experiencing hair loss.

If a patient’s prognosis is positive, chemotherapy is usually administered intravenously, but patients who are not expected to survive only receive the chemotherapy in tablet form, as a means of relieving symptoms.

Chemotherapy is usually given over a period of months, in cycles of treatment that are broken up by rest periods in-between.

Some examples of chemotherapy regimens are described below:

  • ABVD, which refers to the use of adriamycin, bleomycin, vinblastine, and dacarbazine.
  • Stanford V, which uses doxorubicin, bleomycin, vinblastine/vincristine, mechlorethamine, etoposide, and prednisone.
  • BEACOPP, which refers to the use of bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine and prednisone.

Radiatiotherapy is used to treat early-stage Hodgkin’s lymphoma that is still localized to a particular body part. The therapy is administered in short daily sessions between Monday and Friday over the course of several weeks.

Steroids such as prednisolone are sometimes used in combination with chemotherapy drugs for advanced cases of Hodgkin’s lymphoma or in cases where the patient has not responded to initial treatment.

Rituximab is a monoclonal antibody that is used in combination with chemotherapy to treat a particular subtype of Hodgkin’s lymphoma, referred to as the lymphocyte-predominat subtype. The medication is administered intravenously over the course of a few hours.

Further Reading

Last Updated: Jul 6, 2023

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2023, July 06). Hodgkin's Lymphoma Treatment. News-Medical. Retrieved on July 21, 2024 from https://www.news-medical.net/health/Hodgkins-Lymphoma-Treatment.aspx.

  • MLA

    Mandal, Ananya. "Hodgkin's Lymphoma Treatment". News-Medical. 21 July 2024. <https://www.news-medical.net/health/Hodgkins-Lymphoma-Treatment.aspx>.

  • Chicago

    Mandal, Ananya. "Hodgkin's Lymphoma Treatment". News-Medical. https://www.news-medical.net/health/Hodgkins-Lymphoma-Treatment.aspx. (accessed July 21, 2024).

  • Harvard

    Mandal, Ananya. 2023. Hodgkin's Lymphoma Treatment. News-Medical, viewed 21 July 2024, https://www.news-medical.net/health/Hodgkins-Lymphoma-Treatment.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.